1-Deloi N, Khosravinia MR. [Culture of genetic engineering]. Tehran: National Center for Genetic Research and Biotechnology publication; 1994. [In Persian]
2-Esmith P, Hansel K. [Side effect of herbal drug]. Mashhad: Mashhad university publication; 1997. [In Persian]
3-Gardiner P, Kemper KJ, Legedza A, Phillips RS. Factors associated with herb and dietary supplement use by young adults in the United States. BMC Complement Altern Med 2007;7:39.
4-Ernst E. Systematic reviews of herbal medicines. Am J Med 2004;117:533.
5-Ayinehchiy Y. Materia of medical herbs and medicinal plants. Tehran: Tehran University Publication; 1991. p.1035.
7-Rietjens IM, Boersma MG, van der Woude H, Jeurissen SM, Schutte ME, Alink GM. Flavonoids and alkenylbenzenes: mechanisms of mutagenic action and carcinogenic risk. Mutat Res 2005;574(1-2):124–38.
8-Mei N, Guo L, Liu R, Fuscoe JC, Chen T. Gene expression changes induced by the tumorigenic pyrrolizidine alkaloid riddelliine in liver of Big Blue rats. BMC Bioinformatics 2007;8Suppl7:S4.
9-Fu PP, Xia Q, Lin G, Chou MW. Pyrrolizidine alkaloids--genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev 2004;36(1):1–55.
10-Montbriand MJ. Herbs or natural products that may cause cancer and harm part four of a four-part series. Oncol Nurs Forum 2005;32(1):E20-9.
11-Woo Y, Lai D, Arcos J, Argus M. Safrole, estragole and related compounds, In: Arcos JC, Argus MF, Woo Y, eds. Chemical Induction of Cancer. New York: Springer-Verlag; 1988. P. 267.
12- Birdsey MB. A brief description of the cycads. Fed Proc 1972;31:1467-9.
13-Louw WKA, Oelofsen W. Carcinogenic and neurotoxic component in the cycad Encephalartos altensteinii Lehm. (familyZamiaceae). Toxicon 1975;13:447–52.
14-Singh M, Singh N, Khare PB, Rawat AK. Antimicrobial activity of some important Adiantum species used traditionally in indigenous system of medicine. J Ethnopharmacol 2008;115(2):327–9.
15-Heber, PDR for herbal medicine. 3rd ed. London: Thomson publication; 2004. P. 542-3.
16-Imperato F. Sulphate esters of hydroxycinnamic acid-sugar derivatives from Adiantum capillus-veneris. Phytochemistry 1982;21:2717-8.
17-Abdel-Halim OB, Ibraheim ZZ, Shiojima K. Oleanane triterpenes from Adiantum capillus-veneris growing in Egypt. Alex J Pharm Sci 2002;16:87-92.
18-Jankowaski CK, Aumelas A, Thuery P, Reyes-Chilpa R, Jimenez-Estreda M, Barrios H, et al. X-ray,1H/13 C2D and 3D NMR studies of the structures of davallene and adipedatol, two triterpenes isolated from American Adiantum capillus-veneris. Polish J Chem 2004;78:389-408.
19-Guarrera PM, Lucchese F, Medori S. Ethnophytotherapeutical research in the high Molise region (central-southern Italy). J Ethnobiol Ethnomed 2008;4:7.
20-Zargari A. [Medical plants]. Tehran: Tehran University Publications; 1996. P. 513-38. [In Persian]
21-Hooper D. Useful plants and drugs of Iran and Iraq. Chicago: Field Museum Press; 1937. P. 115.
22-Abbasi AM, Khan MA, Ahmad M, Zafar M, Khan H, Muhammad N, et al. Medicinal plants used for the treatment of jaundice and hepatitis based on socio-economic documentation Afr J Biotechnol 2009;8(8):1643-50.
23-Besharat M, Rahimian M, Besharat S, Ghaemi E. Antibacterial effects of Adiantum capillus-veneris ethanolic extract on three pathogenic bacteria in vitro. J Clin Diagn Res 2008;2:1242-3.
24-Guha P, Mukhopadhyay R, Gupta K. Antifungal activity of the crude extracts and extracted phenols from gametophytes and sporophytes of two species of Adiantum. Taiwania 2005;50(4):272-83.
25-Victor B, Maridaas M, Ramesh U, Prabhu JMA. Antibacterial activity of essential oils from the leaves of Adiantum capillus-veneris Linn. Malaysian J Sci 2003;22:65-6.
26-Gupta V, Bansal P, Kumar P, Kaur G. Anti-inflammatory and anti-nociceptive activity of Adiantum capillus. Res J Pharm Tech 2010;3:432-4.
27-Kumar A. Antioxidant effect of Adiantum capillus-veneris Linn. on human lymphocyte: an in vitro study. J Cell Tissue Res 2009;9:1899-902.
28-Purmorad F, Hosseinimehr SJ, Shahabimajd N. Antioxidant activity, phenol and flavonoid contents of some selected Iranian medicinal plants. Afr J Biothecnol 2006;5:1142-5.
29-Konopleva M, Tsao T, Ruvolo P, Stiouf I, Estrov Z, Leysath CE, et al. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 2002;99(1):326–35.
30-Konopleva M, Tsao T, Estrov Z, Lee RM, Wang RY, Jackson CE, et al. The synthetic triterpenoid2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res 2004;64(21):7927–35.
31-Place AE, Suh N, Williams CR, Risingsong R, Honda T, Honda Y, et al. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res 2003;9(7):2798–806.
32-Ito Y, Pandey P, Sporn MB, Datta R, Kharbanda S, Kufe D. The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism. Mol Pharmacol 2001;59(5):1094–9.
33-Hail N Jr, Konopleva M, Sporn M, Lotan R, Andreeff M. Evidence supporting a role for calcium in apoptosis induction by the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9- dien-28-oic acid (CDDO). J Biol Chem 2004;279(12):11179–87.
34-Hyer ML, Shi R, Krajewska M, Meyer C, Lebedeva IV, Fisher PB, et al. Apoptotic activity and mechanism of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic-acid and related synthetic triterpenoids in prostate cancer. Cancer Res 2008;68(8):2927–33.
35-Maron DM, Ames BN. Revised methods for salmonella mutagenicity test. Mutat Res 1983;113(3-4):173-215.
36-Fazlibazzaz S, Izadyar AR. [Antimutagenic properties of fractions of herbal extract of norozak]. Iranian J Med Sci 2001;4:241-50. [In Persian]
37-Ames BN, Mccann J, Yamasaki E. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat Res 1975;31(6):347-64.
38- Mattocks AR. Chemistry and toxicology of pyrrolizidine alkaloids. Florida. Academic Press 1986:4019–27.
39-.Ballantyne B, Marrs T, Syversen T. General and Applied Toxicology. New York: Groves Dictionary INC; 1999.
40-Yazdi E. [Changes in the genetic material]. Tehran: ghalam publications; 1368. [In Persian]
41-Mortelmans K, Zeiger E. The Ames Salmonella/microsome mutagenicity assay. Mutat Res 2000;455(1-2):29–60.
42-Gee P, Maron DM, Ames BN. Detection and classification of mutagens: a set of base-specific Salmonella tester strains. Proc Natl Acad Sci U S A 1994;91:11606–10.
43-Barnes W, Tuley E, Eisenstadt E. Base-sequence analysis of His+ revertants of the hisG46 missense mutation in Salmonella typhimurium. Environmental Mutagenesis 1982;4:297.
44-Willi J. The salmonella typhimutium reverse Mutation Assay. United State Environ Mental Protection Aganey. Health Effects Tests Guidelines 1996;219.
45-United States Environmental Protection Agency. Health Effects Tests Guidelines: OPPTS 870.5265, The Salmonella typhimurium Reverse Mutation Assay EPA712-C-96-219. Boston: United States Environmental Protection Agency; 1996.
46-Organization for Economic Cooperation and Development. OECD Guidelines for the Testing of Chemicals: Bacteria Reverse Mutation Test Guideline 471. City: OECD; 1997.
47-Rajurkar NS, Gaikwad K. Evaluation of phytochemicals, antioxidant activity and elemental content of Adiantum capillus veneris leaves. J Chem Pharma Res 2012;4(1):365-74.
49-Bear WL, Teel RW. Effects of citrus flavonoids on the mutagenicity of heterocyclic amines and on cytochrome P450 1A2 activity. Anticancer Res 2000;20(5B):3609-14.
)